165 related articles for article (PubMed ID: 36935674)
21. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
22. A health economic guide to market access of biosimilars.
Simoens S; Vulto AG
Expert Opin Biol Ther; 2021 Jan; 21(1):9-17. PubMed ID: 33206021
[No Abstract] [Full Text] [Related]
23. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
Whalen J
Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
[TBL] [Abstract][Full Text] [Related]
24. Differences in time to patient access to innovative cancer medicines in six European countries.
Vancoppenolle JM; Franzen N; Koole SN; Retèl VP; van Harten WH
Int J Cancer; 2024 Mar; 154(5):886-894. PubMed ID: 37864395
[TBL] [Abstract][Full Text] [Related]
25. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
26. Policies for biosimilar uptake in Europe: An overview.
Moorkens E; Vulto AG; Huys I; Dylst P; Godman B; Keuerleber S; Claus B; Dimitrova M; Petrova G; Sović-Brkičić L; Slabý J; Šebesta R; Laius O; Karr A; Beck M; Martikainen JE; Selke GW; Spillane S; McCullagh L; Trifirò G; Vella Bonanno P; Mack A; Fogele A; Viksna A; Władysiuk M; Mota-Filipe H; Meshkov D; Kalaba M; Mencej Bedrač S; Fürst J; Zara C; Skiöld P; Magnússon E; Simoens S
PLoS One; 2017; 12(12):e0190147. PubMed ID: 29284064
[TBL] [Abstract][Full Text] [Related]
27. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
28. Potential Cost-Savings From the Use of the Biosimilars in Slovakia.
Tesar T; Golias P; Kobliskova Z; Wawruch M; Kawalec P; Inotai A
Front Public Health; 2020; 8():431. PubMed ID: 32974261
[No Abstract] [Full Text] [Related]
29. Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.
Leyens L; Brand A
Public Health Genomics; 2016; 19(3):187-91. PubMed ID: 27238553
[TBL] [Abstract][Full Text] [Related]
30. Biosimilars: A Value Proposition.
de Mora F
BioDrugs; 2019 Aug; 33(4):353-356. PubMed ID: 31175631
[TBL] [Abstract][Full Text] [Related]
31. Biosimilars and market access: a question of comparability and costs?
Simoens S; Verbeken G; Huys I
Target Oncol; 2012 Dec; 7(4):227-31. PubMed ID: 22249657
[TBL] [Abstract][Full Text] [Related]
32. Time From Marketing Authorization to Reimbursement of Medicines in Greece After the Introduction of the Health Technology Assessment Process From July 2018 to April 2022.
Beletsi A; Stefanou G; Kourlaba G
Value Health Reg Issues; 2023 Jul; 36():58-65. PubMed ID: 37030032
[TBL] [Abstract][Full Text] [Related]
33. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
[TBL] [Abstract][Full Text] [Related]
34. Biosimilars in IBD: from theory to practice.
Danese S; Bonovas S; Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol; 2017 Jan; 14(1):22-31. PubMed ID: 27729659
[TBL] [Abstract][Full Text] [Related]
35. Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
Pivot X; Aulagner G; Blay JY; Fumoleau P; Kaliski A; Sarkozy F; Limat S
Anticancer Drugs; 2015 Nov; 26(10):1009-16. PubMed ID: 26352219
[TBL] [Abstract][Full Text] [Related]
36. The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia.
Tesar T; Golias P; Masarykova L; Kawalec P; Inotai A
Front Pharmacol; 2021; 12():795002. PubMed ID: 34966285
[No Abstract] [Full Text] [Related]
37. Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel.
Mahtani R; Niyazov A; Arondekar B; Lewis K; Rider A; Massey L; Lux MP
Breast; 2022 Dec; 66():236-244. PubMed ID: 36368161
[TBL] [Abstract][Full Text] [Related]
38. Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries.
Kawalec P; Stawowczyk E; Tesar T; Skoupa J; Turcu-Stiolica A; Dimitrova M; Petrova GI; Rugaja Z; Männik A; Harsanyi A; Draganic P
Front Pharmacol; 2017; 8():288. PubMed ID: 28642700
[No Abstract] [Full Text] [Related]
39. [Trastuzumab and its biosimilars].
Sarosiek T; Morawski P
Pol Merkur Lekarski; 2018 May; 44(263):253-257. PubMed ID: 29813044
[TBL] [Abstract][Full Text] [Related]
40. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
Jahnz-Rozyk K; Wiesik-Szewczyk E;
Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
